Contributions
Abstract: PB1662
Type: Publication Only
Session title: Myeloma and other monoclonal gammopathies - Clinical
Background
The prevalence of multiple myeloma is increasing and there is a need to evaluate the associated escalating therapy costs(1). The MYX.1 phase II trial showed that high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone (wKCD) is efficacious in relapsed and refractory disease (2,3). We conducted a descriptive cost analysis, from the perspective of the Canadian public healthcare system, using trial data.
Aims
The goal of this secondary analysis was to determine the total cost of wKCD per patient with a description of per cycle costs and estimated annual costs.
Methods
The primary outcome was the mean total cost per patient. Resource utilization data were collected from all 75 patients enrolled in the MYX.1 trial over a trial time horizon. Costs are presented in Canadian dollars (2020).
Results
The cost of treatment was calculated from the time of patient enrollment until the time of the second data lock in June 2019. The mean total cost per patient was $203,336.08 (range $17,891.27 – $505,583.55) Canadian dollars (CAD, where 1 CAD = 0.65 Euro (EUR)). The median number of cycles was 15. The mean cost per patient per cycle was $14,081.45. The predominant cost driver was the cost of chemotherapy accounting for an average of $179,332.78 per patient or $12,419.17 per patient per cycle. Carfilzomib acquisition accounted for the majority of chemotherapy costs – $162,471.65 total per patient or $11,251.50 per patient per cycle. Fifty-six percent (56%) of patients had at least one hospitalization during the trial period with an average cost of $12,657.86 per hospitalization. The average cost to treat each patient with thrombotic microangiopathy (TMA) was $18,863.32 including the cost of hospitalizations and therapeutic plasma exchange.
Conclusion
High-dose wKCD is an active triplet regimen for RRMM associated with reduced total cost compared with twice weekly regimens.
Keyword(s):
Abstract: PB1662
Type: Publication Only
Session title: Myeloma and other monoclonal gammopathies - Clinical
Background
The prevalence of multiple myeloma is increasing and there is a need to evaluate the associated escalating therapy costs(1). The MYX.1 phase II trial showed that high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone (wKCD) is efficacious in relapsed and refractory disease (2,3). We conducted a descriptive cost analysis, from the perspective of the Canadian public healthcare system, using trial data.
Aims
The goal of this secondary analysis was to determine the total cost of wKCD per patient with a description of per cycle costs and estimated annual costs.
Methods
The primary outcome was the mean total cost per patient. Resource utilization data were collected from all 75 patients enrolled in the MYX.1 trial over a trial time horizon. Costs are presented in Canadian dollars (2020).
Results
The cost of treatment was calculated from the time of patient enrollment until the time of the second data lock in June 2019. The mean total cost per patient was $203,336.08 (range $17,891.27 – $505,583.55) Canadian dollars (CAD, where 1 CAD = 0.65 Euro (EUR)). The median number of cycles was 15. The mean cost per patient per cycle was $14,081.45. The predominant cost driver was the cost of chemotherapy accounting for an average of $179,332.78 per patient or $12,419.17 per patient per cycle. Carfilzomib acquisition accounted for the majority of chemotherapy costs – $162,471.65 total per patient or $11,251.50 per patient per cycle. Fifty-six percent (56%) of patients had at least one hospitalization during the trial period with an average cost of $12,657.86 per hospitalization. The average cost to treat each patient with thrombotic microangiopathy (TMA) was $18,863.32 including the cost of hospitalizations and therapeutic plasma exchange.
Conclusion
High-dose wKCD is an active triplet regimen for RRMM associated with reduced total cost compared with twice weekly regimens.
Keyword(s):